Business Description
China SXT Pharmaceuticals Inc
ISIN : VGG2161P1403
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.56 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -1.13 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -1.36 | |||||
Beneish M-Score | -2.78 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -76.2 | |||||
3-Year EBITDA Growth Rate | 65.1 | |||||
3-Year EPS without NRI Growth Rate | 66.6 | |||||
3-Year FCF Growth Rate | 64.2 | |||||
3-Year Book Growth Rate | -77 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.14 | |||||
9-Day RSI | 43.74 | |||||
14-Day RSI | 44.27 | |||||
6-1 Month Momentum % | -40.23 | |||||
12-1 Month Momentum % | 413.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.51 | |||||
Cash Ratio | 1.36 | |||||
Days Inventory | 160.95 | |||||
Days Sales Outstanding | 250.46 | |||||
Days Payable | 351.64 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -314.9 | |||||
Shareholder Yield % | -19.68 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 28.72 | |||||
Operating Margin % | -130.38 | |||||
Net Margin % | -160.6 | |||||
FCF Margin % | -99.55 | |||||
ROE % | -27.58 | |||||
ROA % | -13.82 | |||||
ROIC % | -23.77 | |||||
3-Year ROIIC % | 51.81 | |||||
ROC (Joel Greenblatt) % | -264.04 | |||||
ROCE % | -22.11 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.23 | |||||
PB Ratio | 0.1 | |||||
Price-to-Tangible-Book | 0.09 | |||||
EV-to-EBIT | 2.87 | |||||
EV-to-EBITDA | 3.11 | |||||
EV-to-Revenue | -3.8 | |||||
EV-to-FCF | 3.79 | |||||
Price-to-Projected-FCF | 0.06 | |||||
Price-to-Net-Current-Asset-Value | 0.26 | |||||
Price-to-Net-Cash | 0.45 | |||||
Earnings Yield (Greenblatt) % | 34.82 | |||||
FCF Yield % | -91.51 |